Anthropic is aggressively expanding beyond general-purpose AI into specialized markets like drug discovery and life sciences, while simultaneously renegotiating pricing agreements with major partners to boost profitability ahead of its anticipated initial public offering. The company launched Claude Science, a dedicated AI product for scientists and pharmaceutical companies, and released an upgraded version of its Sonnet model, while also switching its Amazon billing structure to extract higher margins from one of its largest partners.

What Is Claude Science and Why Does It Matter for Drug Discovery?

Claude Science represents Anthropic's first product specifically designed for the life sciences sector. The tool highlights 3D protein structure rendering and drug discovery as core applications, aiming to help scientists accelerate the early stages of drug development, including molecular design. The product is available to both individual paying users and enterprise subscription customers globally.

Anthropic has already built partnerships with major pharmaceutical companies. Novo Nordisk has applied Claude in drug discovery, clinical documentation, and regulatory filings, while AstraZeneca uses Claude to scale its research and development efforts. The company also acquired biotech startup Coefficient Bio in April to strengthen its life sciences capabilities.

"We believe that by working in the scientific fields, particularly life sciences and healthcare, we can have a scalable, positive impact on humanity," stated Eric Kauderer-Abrams, Head of Life Sciences at Anthropic.

Eric Kauderer-Abrams, Head of Life Sciences at Anthropic

Kauderer-Abrams emphasized that Claude Science aims to narrow a significant gap between cutting-edge AI capabilities and what scientists actually have access to in practice. He noted that the company plans to expand into clinical phases next and is exploring ways to improve physical laboratory experiments, including potential integration with robotics.

How Is Anthropic Positioning Its Updated Claude Sonnet Model?

On the same day as the Claude Science launch, Anthropic released Sonnet 5, the latest version of its mid-tier model. The company claims that Sonnet 5's agent capabilities are approaching those of its flagship Opus model, but at a significantly lower cost. This positioning is designed to bridge the gap between high-end flagship models and lightweight alternatives, offering enterprise customers a balance between performance and affordability.

Sonnet 5 is now available across all subscription tiers. Free and Pro users have access to it by default, while Max, Team, and Enterprise users can also use the model. To demonstrate its real-world capabilities, Anthropic tested Sonnet 5 against two benchmarks: BrowseComp, which assesses agent search ability, and OSWorld-Verified, which tests computer operation skills. In both tests, Sonnet 5 consistently outperformed Sonnet 4.6, though Opus 4.8 remains the most precise option.

Why Is Anthropic Renegotiating Pricing With Amazon?

While expanding into new customer segments and upgrading its technology, Anthropic is also reassessing profit margins from existing core partnerships. According to reporting on the company's business strategy, Anthropic has recently renegotiated agreements with Amazon, switching Claude's pricing model from compute-hours to token-based billing. This change is expected to increase Amazon's costs for using Claude in shopping, programming, and office AI products.

This pricing shift reflects Anthropic's broader focus on profitability as it prepares for public markets. The company's inference infrastructure gross margin has soared past 70 percent, indicating strong underlying economics. The token-based pricing adjustment sends a clear signal to the market about Anthropic's bargaining power and its shift from early-stage expansion toward higher profitability and business monetization.

Steps to Understanding Anthropic's Pre-IPO Strategy

• Market Expansion: Anthropic is entering high-value enterprise segments like pharmaceuticals and life sciences, where customers have significant budgets and willingness to pay for specialized AI capabilities.
• Pricing Optimization: The company is renegotiating terms with existing partners to shift from infrastructure-based pricing to usage-based models, which can generate higher revenue per transaction.
• Product Tiering: Anthropic is releasing models at different performance and cost levels, such as Sonnet 5, to capture customers across the market spectrum rather than forcing all users toward expensive flagship models.
• Strategic Acquisitions: The acquisition of Coefficient Bio and partnerships with major pharmaceutical companies position Anthropic as a serious player in life sciences AI, a sector with substantial growth potential.

What Are the Biosecurity Concerns Around Powerful AI Models?

As Anthropic accelerates commercialization, it faces growing scrutiny around security and biosecurity risks. CEO Dario Amodei warned that societal awareness of AI's risks in biology remains low compared to cybersecurity awareness. He and other AI developers have cautioned that bad actors could use relevant models to create new pathogens or bioweapons.

"Inside pharmaceutical companies, people routinely handle dangerous biological materials and have their own operating procedures. We can learn from these practices, perhaps we shouldn't open access to anyone before verifying their identity," said Dario Amodei.

Dario Amodei, CEO at Anthropic

Amodei argued that only individuals or organizations with verified credentials should be allowed to access powerful bio-AI models with potentially dangerous applications. Notably, Claude Science currently operates on existing models and does not possess advanced biological capabilities. Anthropic plans to establish a trusted access program for biological applications, inspired by practices in the cybersecurity sector.

Where Does Anthropic Stand in the Competitive Landscape?

Anthropic is not alone in pursuing scientific applications as a strategic priority. OpenAI launched GPT-Rosalind in April, a cutting-edge model designed for biological research, drug discovery, and translational medicine, aiming to translate medical research into clinical solutions. This competitive move underscores the growing importance of AI in the pharmaceutical sector.

Anthropic is currently at a critical pre-listing stage. The company could go public as soon as this year, with a potential valuation exceeding one trillion dollars. Last month, it closed a new funding round with a pre-closing valuation of 900 billion dollars. The launch of Claude Science marks a tangible step toward turning AI capabilities into sustainable enterprise revenue, though the company will need to balance accelerating commercialization with managing biosecurity risks ahead of its debut on the capital markets.